$XBI $74.80 | +1.0%
Table of Contents:
Covid Updates
#NVAX +1.6% Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants. source
#ABCL -1.5% Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
#PFE+0.6% & #BNTX +1.5% Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Pipeline Updates
#CGTX+32.9%
#ATRA +15.7%
#WVE +14.2%
#BLUE +13.4%
#AGEN +10.9% Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress. source
#GBT +8.2% GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease. source
#AVDL +6.8% (aftr mrkt) Avadel Pharmaceuticals Provides Corporate Update
#AKUS +6.3%
#JAGX +2.7% Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China. source
#CORT +1.5% Corcept Therapeutics Initiates ROSELLA – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
#ADCT +0.8% ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents. source
#ALXO +0.5% ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia. source
#CDAK -3.5% Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASOâ„¢-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer. source
#IFRX -7.2% 06-2022-InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19. source
#GRTX -14.3% Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC. source
#NMTR -15.8%
#ICVX -16.8% Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV. source
#ANGN -18.7% (aftr mrkt) ANGION ANNOUNCES DISCONTINUATION OF PHASE 2 TRIAL OF ANG-3070 IN PATIENTS WITH PRIMARY PROTEINURIC KIDNEY DISEASE
#ENDP -26.4%
#ALRN -27.1% Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer. source
#AGRX -36.1%
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#ETNB 89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants. source
#VRCA -6.9% Verrica Announces Proposed Public Offering of Common Stock
#BSGM -9% BioSig Announces Closing of Public Offering of Common Stock
Posted by FS/JM